Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CAR-T in R/R B-ALL
NCT04094766Phase 1Withdrawn
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2017
- Primary completion
- Aug 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BLLCAR-L10D in B-cell acute lymphoblastic leukemia (B-ALL), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Adverse Events at 100 days. Planned start Aug 2017; status: withdrawn.
02
Drugs
BLLCAR-L10D
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04094766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094766.